August 4, 2020 10:29 AM EDT
News Briefing

Karuna and In­cyte scrap pro­grams; More cash for the SPACs

Jason Mast

Editor

Karuna Ther­a­peu­tics has built it­self in­to a $2 bil­lion com­pa­ny off the da­ta of an old Eli Lil­ly drug, when com­bined with tro­spi­um chlo­ride …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times